Business
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal
About this update from Vaxcyte, Inc.
[{"type":"text","content":"New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish commercial manufacturing for Vaxcyte’s broad-spectrum pneumococcal conjugate vaccines (PCVs) to the United States. As a key element of Vaxcyte’s long-term U.S. commercial supply strategy, Thermo Fisher will provide custom commercial fill-finish capacity for the Company’s broad-spectrum PCVs at its Greenville, North Carolina facility. The initiative, including both manufacturing and related services, signifies a long-term U.S. commercial manufacturing commitment for Vaxcyte representing up to $1 billion. “The decision to significantly expand our fill-finish manufacturing capacity in the United States represents an effort to expand our end-to-end supply strategy and align with the increasing focus on domestic biomanufacturing,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “By scaling our fill-finish operations in North Carolina, we’re strengthening our U.S. supply chain, enhancing commercial readiness and deepening our investment in American innovation, infrastructure and jobs — all in service of our mission to deliver high-fidelity vaccines that protect against serious infectious diseases.” About VaxcyteVaxcyte is a U.S.-headquartered vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s lead vaccine candidate is VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and being evaluated in a Phase 2 infant clinical program. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. The Company’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A St...